Methylprednisolone

Medrol has disease-specific endocrine, rheumatic/collagen, dermatologic/allergic, ophthalmic, respiratory, hematologic/neoplastic, nephrotic, gastrointestinal and acute-MS-exacerbation indications. Solu-Medrol IV/IM and Depo-Medrol IM have their own broad disease lists when oral therapy is not feasible and the formulation/route fits. Endocrine replacement generally favors hydrocortisone/cortisone, with mineralocorticoid supplementation when appropriate. Do not interpret the lists as permission to treat every rash, pain or infection with systemic steroids.

Depo-Medrol intra-articular/soft-tissue use is short-term adjunctive treatment of selected arthritic, bursal or tendon-sheath inflammatory disorders. Intralesional indications include specified inflammatory dermatoses, keloids, alopecia areata and selected ganglia. Appropriate sterile placement and infection exclusion are essential; local injections can be systemically absorbed. Solu-Medrol powder is not the acetate suspension and does not inherit these local-use instructions.

Systemic high-dose methylprednisolone should not be used to treat traumatic brain injury; injection labels describe increased mortality in that setting. Steroids may speed MS relapse resolution without changing the ultimate disease course; label legacy relapse regimens are not a complete modern MS protocol. Antimicrobial treatment remains necessary for labeled adjunctive tuberculosis uses. Epidural use is unapproved and intrathecal administration is contraindicated. Solu-Medrol labeling also reports failure to establish benefit in sepsis/septic shock and possible increased mortality in selected patients; its broad high-dose example is not a recommendation for those conditions.

The following label ranges are not substitute disease-specific protocols or universal ceilings.

Depo-Medrol initial general parenteral range is 4–120 mg, with substantial disease/route variation. For temporary oral replacement, its label describes one daily IM dose equal to daily oral Medrol mg; for prolonged effect, a supervised weekly IM dose can use 7 times the oral daily dose. These label examples do not establish equivalence for every depot/route situation.

Long-term therapy needs gradual individualized reduction when disease is controlled. The 2024 ESE/Endocrine Society guidance generally does not require an HPA-prevention taper for a course shorter than 3–4 weeks; longer exposure needs a disease- and adrenal-aware plan near physiologic doses. Do not apply that short-course guidance automatically to repeated/depot exposures. Current/recent steroid users without documented adrenal recovery may need stress coverage; inability to retain oral medicine or hemodynamic instability requires urgent parenteral assessment. No universal daily taper decrement is supplied.

Solu-Medrol: follow exact Act-O-Vial/vial diluent, asepsis and dilution instructions; do not casually mix with other drugs. Depo-Medrol: do not dilute/mix with other solutions; IV use is prohibited, avoid injecting tendon substance/deltoid skin leakage, and use skilled sterile local technique. Label anti-inflammatory comparison is methylprednisolone 4 mg ≈ prednisone/prednisolone 5 mg or hydrocortisone 20 mg for oral/IV use; IM/depot/joint effects may differ substantially. No validated universal renal/hepatic percentage adjustment is supplied.

All selected products: hypersensitivity; systemic fungal infections, with Depo-Medrol’s label exception for localized intra-articular treatment requiring careful assessment. Solu-Medrol adds intrathecal administration, IM use in idiopathic thrombocytopenic purpura, and cow’s-milk hypersensitivity for 40 mg. Depo-Medrol adds intrathecal and IM use in ITP; IV administration is prohibited. Benzyl-alcohol-containing presentations are contraindicated in premature infants and should not be used in neonates per relevant label warnings. Live/attenuated vaccines are contraindicated during immunosuppressive steroid doses.

These selected current U.S. labels have no boxed warning. Serious route-specific neurologic, milk-allergy/preservative and infection/adrenal risks remain important and are not inferred away by absence of a box.

Effects include mood/insomnia changes, appetite/weight gain, hyperglycemia, fluid/BP/potassium effects, infection, bruising/skin atrophy, poor wound healing, cataract/glaucoma, osteoporosis/osteonecrosis and myopathy. Serious allergy, GI perforation/bleeding, adrenal crisis, psychiatric toxicity, thromboembolism and injection cardiac/liver/local complications are reported; many frequencies are uncertain. Acute overdose needs clinical/Poison Help advice (U.S. 1-800-222-1222) and supportive treatment. Chronic excess requires supervised adjustment rather than abrupt withdrawal of needed steroid therapy.

Review all oral, injectable, inhaled, topical and local steroid use together. Recent joint injections or multiple formulations can increase HPA risk; strong CYP3A4 inhibitors can magnify exposure. Do not treat a local injection as unrelated to the systemic taper/stress assessment.

Selected labels require weighing maternal benefit against fetal risk; adequate controlled human studies are lacking, and animal developmental findings do not establish safety. Observe exposed newborns for hypoadrenalism after substantial maternal systemic treatment. Systemic steroids enter milk and can affect infant growth/endogenous steroid production; injectable labels advise choosing nursing versus drug continuation according to maternal need. Benzyl alcohol can cross the placenta in preserved formulations; check the exact preparation.

Pediatric roles are disease-specific; selected soluble-injection label discusses nephrotic syndrome evidence above 2 years and aggressive leukemia/lymphoma above 1 month, not a universal minimum for every steroid indication. Preserved products are unsuitable/contraindicated in the specified neonate/premature-infant groups. Use the lowest effective dose and monitor linear growth, BP, weight, eyes, infection and psychosocial effects. Premature infants can develop methylprednisolone-associated hypertrophic cardiomyopathy. Older adults need cautious selection considering organ function, bone, glucose, BP and other drugs.

No universal renal dose algorithm is given. Sodium retention/potassium loss can worsen renal/HF/HTN disease; monitor response and labs. Cirrhosis and hypothyroidism can enhance steroid effects, while hyperthyroidism can increase clearance. Use cautious individualized doses and assess systemic sclerosis renal-crisis risk. HPA recovery is variable; no normal single test or short symptom-free interval automatically rules out risk after substantial/repeated exposure.

Glucocorticoids modify inflammatory/immune responses and carbohydrate, protein, lipid, fluid and electrolyte metabolism. Methylprednisolone has potent anti-inflammatory activity with less sodium-retaining tendency than hydrocortisone, but high doses still cause mineral/fluid effects. The soluble succinate and depot acetate retain glucocorticoid activity while their administration/absorption patterns differ.

Oral / soluble succinate

Oral glucocorticoids are readily absorbed; IV succinate can show effects within about 1 hour. Clinical duration varies and is not a universal fixed half-life.

Depot acetate

Suspension is practically insoluble in water and supports prolonged IM/local exposure; local injections can produce systemic effects.

Metabolism / interactions

Hepatic enzyme changes and CYP3A4 interacting drugs influence effect/exposure; cirrhosis or thyroid-status changes can change dose needs.

Conversion limits

Oral/IV anti-inflammatory equivalent doses are not a direct conversion algorithm for IM depot or joint injection. These selected U.S. labels do not establish one quantified elimination half-life for all formulations.

Track clinical response and lowest effective dose; assess BP/weight/edema, glucose, electrolytes, infection/exposure risks, mood/sleep, GI symptoms, bone/muscle and growth in children. Screen HBV before prolonged/immunosuppressive therapy and evaluate other infections by risk. Monitor eyes with prolonged treatment; soluble injection label specifies IOP assessment if treatment continues > 6 weeks. High-dose IV needs cardiovascular and delayed liver-injury vigilance; local injection needs aseptic/infection follow-up. HPA assessment and stress coverage are individualized; the guideline allows clinical taper or morning cortisol near physiologic dosing rather than indiscriminate routine testing.

Know the exact tablet/ester/route and follow the individualized course rather than reusing a Dosepak for another illness. Do not stop prolonged steroid therapy without supervision; tell all treating clinicians about current/recent steroids, including local injections. Ask about illness/surgery stress dosing and urgent symptoms of adrenal crisis. Report infection/varicella-measles exposure, severe mood symptoms, black stools/severe abdominal pain, vision change or post-injection fever/swelling promptly. Discuss vaccines, pregnancy/nursing and all medicines; carry the prescribed steroid-alert information when appropriate.

Medrol 4 mg: white elliptical scored tablet marked MEDROL 4; example bottle of 100 NDC 0009-0056-02. Dosepak NDC 0009-0056-04 contains 21 of the 4 mg tablets and is not child-resistant. Pharmacia & Upjohn, a Pfizer subsidiary, distributes the selected products.

Medrol tablets and unreconstituted Solu-Medrol: 20–25°C; protect soluble powder from light. Reconstituted Solu-Medrol not further diluted: 20–25°C, use within 48 hours. Further dilution: microbiologically use immediately unless preparation precludes contamination; chemical/physical stability is 4 hours below 25°C or 24 hours at 2–8°C, not a blanket microbiological guarantee. Depo-Medrol: 20–25°C; do not autoclave or mix/dilute. Discard remaining single-dose suspension; preserved multidose vials require meticulous aseptic technique and the exact institutional/product in-use policy, not an invented universal discard interval.